2024-03-28T14:34:05Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/1357322021-06-07T11:57:05Zcom_10261_112com_10261_1col_10261_365
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
Paiva, Bruno
Puig, Noemi
Ocio, Enrique M.
San-Segundo, Laura
Escalante, Ricardo
San Miguel, Jesús F.
Melero, Ignacio
Despite remarkable therapeutic improvement in multiple myeloma (MM), prognosis is very poor once patients become refractory to or ineligible for proteasome inhibitors and immunomodulatory drugs. Accordingly, new drugs are clearly needed for this patient population, and extensive efforts are leading to a new breed of antimyeloma drugs.
Peer Reviewed
2016-08-22T10:20:46Z
2016-08-22T10:20:46Z
2015
2016-08-22T10:20:47Z
artículo
http://purl.org/coar/resource_type/c_6501
doi: 10.1038/leu.2015.79
e-issn: 1476-5551
issn: 0887-6924
Leukemia 29(10): 2110-2113 (2015)
http://hdl.handle.net/10261/135732
10.1038/leu.2015.79
Sí
none
Nature Publishing Group